Clinical data | |
---|---|
Trade names | Velexbru |
Other names | GS-4059; ONO-4059 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C25H22N6O3 |
Molar mass | 454.490 g·mol−1 |
Tirabrutinib (brand name Velexbru) is a drug used for the treatment of autoimmune disorders and hematological malignancies. [1] [2]
Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. [1] In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences [3] in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis. [1]
Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase. [4]
Clinical data | |
---|---|
Trade names | Velexbru |
Other names | GS-4059; ONO-4059 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C25H22N6O3 |
Molar mass | 454.490 g·mol−1 |
Tirabrutinib (brand name Velexbru) is a drug used for the treatment of autoimmune disorders and hematological malignancies. [1] [2]
Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. [1] In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences [3] in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis. [1]
Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase. [4]